Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
22
CPHI Quote, Financials, Valuation and Earnings
Last price:
$1.33
Seasonality move
:
13.36%
Day range:
$1.30 - $1.35
52-week range:
$1.20 - $3.35
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.06x
P/B ratio:
0.50x
Volume:
12.9K
Avg. volume:
38.3K
1-year change:
-30.69%
Market cap:
$4.3M
Revenue:
$4.5M
EPS (TTM):
-$1.03
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, China Pharma Holdings, Inc. has -- downside to fair value with a price target of -- per share.
CPHI vs. S&P 500
-
Over the past 5 trading days, China Pharma Holdings, Inc. has underperformed the S&P 500 by -4.61% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
China Pharma Holdings, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
China Pharma Holdings, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter China Pharma Holdings, Inc. reported revenues of $756.2K.
Earnings Growth
-
China Pharma Holdings, Inc. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter China Pharma Holdings, Inc. reported earnings per share of -$0.17.
Enterprise value:
7.5M
EV / Invested capital:
0.63x
Price / LTM sales:
1.06x
EV / EBIT:
--
EV / Revenue:
1.86x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-44.50x
Price / Operating cash flow:
143.41x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$1.1M
Return On Assets:
-21.89%
Net Income Margin (TTM):
-78.72%
Return On Equity:
-43.41%
Return On Invested Capital:
-29.08%
Operating Margin:
-83.06%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $7.8M | $5.5M | $4.1M | $1.1M | $756.2K | |
| Gross Profit | -$330.7K | -$2.3M | -$1.1M | -$624.5K | -$257.6K | |
| Operating Income | -$2.7M | -$4.6M | -$3.2M | -$1.1M | -$628.1K | |
| EBITDA | -$37.8K | -$1.7M | -$1.8M | -$388.3K | -$272.1K | |
| Diluted EPS | -$1.88 | -$0.34 | -$1.03 | -$0.06 | -$0.17 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $4.1M | $5.6M | $5.8M | $3.7M | $2.3M | |
| Total Assets | $18.2M | $16.2M | $15.4M | $13.5M | $16M | |
| Current Liabilities | $10.5M | $12.6M | $7.1M | $4.8M | $6.6M | |
| Total Liabilities | $11.3M | $13.4M | $9.2M | $6.9M | $7.5M | |
| Total Equity | $6.9M | $2.8M | $6.1M | $6.5M | $8.5M | |
| Total Debt | $4.4M | $7.6M | $4.2M | $2.8M | $2.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$92.8K | -$727.2K | $234.7K | -$47K | -$237K | |
| Cash From Investing | $20.3K | -$23.4K | -$404.3K | $9.2K | -$40.6K | |
| Cash From Financing | -$629.3K | $50.9K | -$214.6K | $6.8K | -$122.2K | |
| Free Cash Flow | -$65.4K | -$750.6K | -$169.6K | -$37.8K | -$277.6K | |
CPHI
Sector
Market Cap
$4.3M
$28.1M
Price % of 52-Week High
39.1%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
1.54%
-1.49%
1-Year Price Total Return
-30.69%
-17.13%
Beta (5-Year)
1.028
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.43
200-day SMA
Sell
Level
$1.80
Bollinger Bands (100)
Sell
Level
1.46 - 1.86
Chaikin Money Flow
Sell
Level
-2.2M
20-day SMA
Sell
Level
$1.58
Relative Strength Index (RSI14)
Sell
Level
34.12
ADX Line
Sell
Level
10.55
Williams %R
Buy
Level
-98.2759
50-day SMA
Sell
Level
$1.63
MACD (12, 26)
Sell
Level
-0.08
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Neutral
Level
6.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.297)
Sell
CA Score
(Annual)
Level (-1.721)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (3.5668)
Sell
Piotroski F Score
(Annual)
Level (3)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
China Pharma Holdings, Inc. engages in the development, manufacture, and marketing of pharmaceutical products. The firm’s product portfolio includes Central Nervous System (CNS) and Cerebral-Cardiovascular Diseases, Anti-infection and Respiratory Diseases, Digestive Diseases, Comprehensive Healthcare, and Protective Products. The company was founded by Zhi Lin Li on January 28, 1999 and is headquartered in Haikou, China.
Stock Forecast FAQ
In the current month, CPHI has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CPHI average analyst price target in the past 3 months is --.
-
Where Will China Pharma Holdings, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that China Pharma Holdings, Inc. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About China Pharma Holdings, Inc.?
Analysts are divided on their view about China Pharma Holdings, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that China Pharma Holdings, Inc. is a Sell and believe this share price will rise from its current level to --.
-
What Is China Pharma Holdings, Inc.'s Price Target?
The price target for China Pharma Holdings, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CPHI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for China Pharma Holdings, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of CPHI?
You can purchase shares of China Pharma Holdings, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase China Pharma Holdings, Inc. shares.
-
What Is The China Pharma Holdings, Inc. Share Price Today?
China Pharma Holdings, Inc. was last trading at $1.33 per share. This represents the most recent stock quote for China Pharma Holdings, Inc.. Yesterday, China Pharma Holdings, Inc. closed at $1.31 per share.
-
How To Buy China Pharma Holdings, Inc. Stock Online?
In order to purchase China Pharma Holdings, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get CPHI Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CPHI
Sector
P/E ratio
--
23.89x
PEG ratio
-0.01x
-0.01x
P/B ratio
0.50x
1.81x
Price / LTM sales
1.06x
1.59x
Growth Metrics
CPHI
Sector
Revenue growth
-31.26%
4.62%
Earnings growth
-160.37%
11.06%
Revenue (5-year growth)
-16.15%
6.5%
Earnings forecast
--
-$0.21
Profitability
CPHI
Sector
Profitability FY 2024
-$2.4M
$3.6M
Return on invested capital
-29.08%
-31.84%
Return on assets
-21.89%
-27.96%
Return on equity
-43.41%
-37.63%
Earnings Date
Last Earnings Date
Dec
25
Next Earnings Date
Dec
25
Estimated Next Earnings Date
Mar
26
Balance Sheet
CPHI
Sector
Total cash
$294.3K
$26.4M
Short term investments
--
$25.7M
Total assets
$15.1M
$76.9M
Long term debt
$2.1M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
87
HUT alert for Dec 25
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
60
GPCR alert for Dec 25
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
